This is the first product named Pabron. At first, Pabron was a cough suppressant mainly made from crude drug extract with cough suppressing effects.

National health insurance begins. With a view toward the growth of the pharmaceutical industry, we decided to expand our operations into ethical drugs. This led us to launch our first ethical drug, Psorion, a prescription drug for the treatment of psoriasis.

Lipovitan D was released when drugs packaged in ampules were the mainstream. It was based on an idea of increasing the volume of the drugs packaged in ampules to reduce the typical medicine smell and to season and cool them for oral ingestion. By inventing the new energy drink culture, Taisho Pharmaceutical became a leader in the OTC drug field.

The export of Lipovitan D to Taiwan marks the start of our overseas operations. Two years later, in 1965, we began exports to Thailand. Southeast Asia became the center of our international sales expansion initiatives.

Promising early-career researchers should never be forced to abandon their work for financial reasons. This was the idea that drove us to establish the Uehara Memorial Foundation. The foundation began providing assistance for research to help the life sciences grow in Japan and promote general health and welfare.

When creating an original antibiotic to world-class standards was considered a highly difficult feat, we released Clarith Tablet, an antibiotic that easily met these international standards and demonstrated the advanced level of our R&D department.
We continued to expand the drug’s applications and improve our manufacturing methods after its release, helping it develop into a treatment sold around the world.

As the market reached maturity, we promoted a strategy of acquiring strong brands to differentiate ourselves in terms of tradition, reliability and quality of products. We took over Colac laxative operations from the P&G Group.

Before that, energy drinks like Lipovitan D were classified as drugs and sold only in pharmacies and drugstores. With the deregulation of pharmaceutical sales, however, they were reclassified as "quasi-drugs." This made it possible to sell Lipovitan D in convenience stores, supermarkets, and even vending machines, making it even more familiar to consumers.

After signing a minoxidil technology introduction contract, we spent 14 years researching and developing RiUP, Japan’s first hair regrowth treatment for male-pattern baldness. RiUP was also Japan’s first direct-to-OTC drug, approved for over-the-counter sales with no intervening prescription pharmaceutical phase.

To address this challenge faced by society in our capacity as a drug manufacturer, we launched Livita, a food and supplement brand covering every area of health. Our goal with Livita is to support people by developing safe and effective products. Following the launch of this brand, we began reinforcing our development of food and supplements as a peripheral part of our self-medication business.

In response to changes in consumer buying patterns and to create new sales opportunities, we launched the direct-to-consumer sales website Taisho Direct. In an easy-to-understand manner, we shared product characteristics and information useful to consumers based on scientific data.

By making Biofermin Pharmaceutical our consolidated subsidiary, we acquired Biofermin, the top brand in the field of intestinal medicine in Japan.

We acquired trademark rights to the OTC drugs owned by U.S. company Bristol-Myers Squibb (BMS) in Asia and PT Bristol-Myers Squibb Indonesia Tbk (BMSI) stock. Full-scale OTC drug operations in Asia started

We acquired all of the shares of Malaysia’s HOE (Hoepharma Holdings Sdn. Bhd.) which has the largest share of that country’s prescription dermatological treatment market. HOE also sells products in 40 countries in and around Asia. This acquisition helped our self-medication business make a major advance into Malaysia, expanding our business base in the Asian region.

Lusfi was released after seven years of research into diabetes treatments. Lusefi is an SGLT2 inhibitor tablet that we created, developed and gained approval to manufacture and sell.

We released LOQOA Tape, an externally applied treatment for osteoarthritis codeveloped with Tokuhon which is a Taisho Pharmaceutical Group company.

Duoc Hau Giang Pharmaceutical JSC (DHG) became a consolidated subsidiary. DHG is a Vietnamese pharmaceutical company that became an equity-method affiliate in 2016.

We acquired the French company UPSA. This gave us a strong foothold in Europe, complementing our existing business base in Japan and Southeast Asia.

We released Nanozora, an anti-TNFα nanobody  preparation which is about one quarter of the regular IgG antibodies in terms of molecular weight. This was joined by an auto-injector with a new dosage form in 2023.

We launched alli, a direct-to-OTC drug and the first-ever visceral fat reducing drug in Japan designed to help fat-bellied people¹ who are working to improve their lifestyles to reduce visceral fat and the circumference of their waists.